There have been conflicting results regarding the effect of proton pump inhibitors (PPIs) as an adjunctive therapy to oral antidiabetic medication (OAM) in those with type 2 diabetes (T2DM). PPIs increase gastrin levels, causing a rise in insulin. No studies have evaluated the duration of PPI therapy and its effect on glycemic control. Medical records across 8 hospitals between 2007 and 2016 were reviewed for 14,602 patients with T2DM (not on insulin therapy) taking PPIs. Values of HbA1c (baseline, follow-up, and the difference between the two) in those prescribed with PPIs and years of therapy were compared to HbA1c values of those who had no record of PPI use. Baseline and follow-up HbA1c for patients on PPIs were 6.8 and 7.0, respectively, compared to 7.1 and 7.2 in their untreated counterparts ( in both comparisons). For both groups, an increase in baseline HbA1c was seen with time. Those on PPI had an increase in HbA1c of 0.16 compared to 0.08 in those not prescribed PPI. Our results show no relationship between the length of PPI therapy and HbA1c reduction.

中文翻译：

---

长期使用质子泵抑制剂对 2 型糖尿病患者血糖控制的影响

关于质子泵抑制剂 (PPI) 作为口服抗糖尿病药物 (OAM) 的辅助治疗对 2 型糖尿病 (T2DM) 患者的效果存在矛盾的结果。PPI 增加胃泌素水平，导致胰岛素升高。没有研究评估 PPI 治疗的持续时间及其对血糖控制的影响。对 2007 年至 2016 年间 8 家医院的 14,602 名服用 PPI 的 T2DM（未接受胰岛素治疗）患者的医疗记录进行了审查。将使用 PPI 和治疗年限的患者的 HbA1c 值（基线、随访和两者之间的差异）与没有 PPI 使用记录的患者的 HbA1c 值进行比较。PPI 患者的基线和随访 HbA1c 分别为 6.8 和 7.0，而未接受治疗的患者为 7.1 和 7.2（在这两个比较中）。两组的基线 HbA1c 均随时间增加。服用 PPI 的人 HbA1c 增加了 0.16，而未服用 PPI 的人 HbA1c 增加了 0.08。我们的结果显示 PPI 治疗时间与 HbA1c 降低之间没有关系。